ID

35154

Description

A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02386111

Link

https://clinicaltrials.gov/show/NCT02386111

Keywords

Versions (1)
  1. 2/20/19 2/20/19 -
Copyright Holder

See clincaltrials.gov

Uploaded on

February 20, 2019

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Carcinoma, Renal Cell NCT02386111

English

Eligibility Carcinoma, Renal Cell NCT02386111

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. histologically confirmed diagnosis of predominant clear cell renal cell carcinoma.
Description

Clear Cell Renal Cell Carcinoma predominant

Data type

boolean

Alias
UMLS CUI [1,1]
C0279702
UMLS CUI [1,2]
C1542147
2. advanced metastatic disease
Description

Neoplasm Metastasis Advanced

Data type

boolean

Alias
UMLS CUI [1,1]
C0027627
UMLS CUI [1,2]
C0205179
3. documented progressive disease based on radiographic, clinical or pathologic assessment during or subsequent to last therapy.
Description

Progressive Disease

Data type

boolean

Alias
UMLS CUI [1]
C1335499
4. for phase l, no more than 3 prior anticancer regimens and for phase ll, no more than 1 prior anticancer regimen (il-2 or interferon do not count towards the total).
Description

Cancer treatment Quantity | Count Independent of Interleukin-2 | Count Independent of Interferon

Data type

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C1265611
UMLS CUI [2,1]
C0750480
UMLS CUI [2,2]
C0332291
UMLS CUI [2,3]
C0021756
UMLS CUI [3,1]
C0750480
UMLS CUI [3,2]
C0332291
UMLS CUI [3,3]
C3652465
5. measurable (target) disease.
Description

Measurable Disease

Data type

boolean

Alias
UMLS CUI [1]
C1513041
6. life expectancy ≥ 12 weeks.
Description

Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
7. if of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 70 days following last treatment dose.
Description

Females & males of reproductive potential Contraceptive methods

Data type

boolean

Alias
UMLS CUI [1,1]
C4034483
UMLS CUI [1,2]
C0700589
8. must have available tumor tissue and consent to biopsy while on study.
Description

Availability of Tumor tissue sample | Consent Biopsy

Data type

boolean

Alias
UMLS CUI [1,1]
C0470187
UMLS CUI [1,2]
C0475358
UMLS CUI [2,1]
C1511481
UMLS CUI [2,2]
C0005558
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. prior therapy with an anti-cd27 antibody.
Description

CD27 Antibody

Data type

boolean

Alias
UMLS CUI [1,1]
C0054949
UMLS CUI [1,2]
C0003241
2. previous treatment with sunitinib.
Description

Prior Therapy Sunitinib

Data type

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C1176020
3. use of any experimental immunotherapy.
Description

Immunotherapy Investigational

Data type

boolean

Alias
UMLS CUI [1,1]
C0021083
UMLS CUI [1,2]
C1517586
4. chemotherapy within 21 days or at least 5 half-lives (whichever is shorter) prior to the planned start of study treatment.
Description

Chemotherapy

Data type

boolean

Alias
UMLS CUI [1]
C0392920
5. systemic radiation therapy within 4 weeks, prior focal radiotherapy within 2 weeks, or radiopharmaceuticals (strontium, samarium) within 8 weeks prior to the first dose of study treatment.
Description

Systemic Radiation Therapy | Therapeutic radiology procedure Focal | Radiopharmaceuticals | Strontium | Samarium

Data type

boolean

Alias
UMLS CUI [1]
C2985381
UMLS CUI [2,1]
C1522449
UMLS CUI [2,2]
C0205234
UMLS CUI [3]
C0182638
UMLS CUI [4]
C0038467
UMLS CUI [5]
C0036147
6. use of immunosuppressive medications within 4 weeks or systemic corticosteroids within 2 weeks prior to first dose of study treatment.
Description

Immunosuppressive Agents | CORTICOSTEROIDS FOR SYSTEMIC USE

Data type

boolean

Alias
UMLS CUI [1]
C0021081
UMLS CUI [2]
C3653708
7. other prior malignancy, except for adequately treated basal or squamous cell skin cancer or in situ cancers; or any other cancer from which the patient has been disease-free for at least 3 years.
Description

Cancer Other | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated | Exception Carcinoma in Situ Treated | Exception Disease Free Duration

Data type

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007117
UMLS CUI [2,3]
C1522326
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0553723
UMLS CUI [3,3]
C1522326
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0007099
UMLS CUI [4,3]
C1522326
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0012634
UMLS CUI [5,3]
C0332296
UMLS CUI [5,4]
C0449238
8. active, untreated central nervous system metastases.
Description

CNS metastases Untreated

Data type

boolean

Alias
UMLS CUI [1,1]
C0686377
UMLS CUI [1,2]
C0332155
9. active autoimmune disease or a documented history of autoimmune disease.
Description

Autoimmune Disease

Data type

boolean

Alias
UMLS CUI [1]
C0004364
10. active diverticulitis.
Description

Diverticulitis

Data type

boolean

Alias
UMLS CUI [1]
C0012813
11. significant cardiovascular disease including chf or poorly controlled hypertension.
Description

Cardiovascular Disease | Congestive heart failure | Poor hypertension control

Data type

boolean

Alias
UMLS CUI [1]
C0007222
UMLS CUI [2]
C0018802
UMLS CUI [3]
C0421190
12. impairment of gastrointestinal function or gastrointestinal disease that may alter the absorption of sunitinib.
Description

Impaired gastrointestinal system function | Gastrointestinal Disease Changing Absorption Sunitinib

Data type

boolean

Alias
UMLS CUI [1]
C0232459
UMLS CUI [2,1]
C0017178
UMLS CUI [2,2]
C0392747
UMLS CUI [2,3]
C0237442
UMLS CUI [2,4]
C1176020
Back to the top of the page

Similar models

Eligibility Carcinoma, Renal Cell NCT02386111

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Clear Cell Renal Cell Carcinoma predominant
Item
1. histologically confirmed diagnosis of predominant clear cell renal cell carcinoma.
boolean
C0279702 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Neoplasm Metastasis Advanced
Item
2. advanced metastatic disease
boolean
C0027627 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
Progressive Disease
Item
3. documented progressive disease based on radiographic, clinical or pathologic assessment during or subsequent to last therapy.
boolean
C1335499 (UMLS CUI [1])
Cancer treatment Quantity | Count Independent of Interleukin-2 | Count Independent of Interferon
Item
4. for phase l, no more than 3 prior anticancer regimens and for phase ll, no more than 1 prior anticancer regimen (il-2 or interferon do not count towards the total).
boolean
C0920425 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0750480 (UMLS CUI [2,1])
C0332291 (UMLS CUI [2,2])
C0021756 (UMLS CUI [2,3])
C0750480 (UMLS CUI [3,1])
C0332291 (UMLS CUI [3,2])
C3652465 (UMLS CUI [3,3])
Measurable Disease
Item
5. measurable (target) disease.
boolean
C1513041 (UMLS CUI [1])
Life Expectancy
Item
6. life expectancy ≥ 12 weeks.
boolean
C0023671 (UMLS CUI [1])
Females & males of reproductive potential Contraceptive methods
Item
7. if of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 70 days following last treatment dose.
boolean
C4034483 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Availability of Tumor tissue sample | Consent Biopsy
Item
8. must have available tumor tissue and consent to biopsy while on study.
boolean
C0470187 (UMLS CUI [1,1])
C0475358 (UMLS CUI [1,2])
C1511481 (UMLS CUI [2,1])
C0005558 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
CD27 Antibody
Item
1. prior therapy with an anti-cd27 antibody.
boolean
C0054949 (UMLS CUI [1,1])
C0003241 (UMLS CUI [1,2])
Prior Therapy Sunitinib
Item
2. previous treatment with sunitinib.
boolean
C1514463 (UMLS CUI [1,1])
C1176020 (UMLS CUI [1,2])
Immunotherapy Investigational
Item
3. use of any experimental immunotherapy.
boolean
C0021083 (UMLS CUI [1,1])
C1517586 (UMLS CUI [1,2])
Chemotherapy
Item
4. chemotherapy within 21 days or at least 5 half-lives (whichever is shorter) prior to the planned start of study treatment.
boolean
C0392920 (UMLS CUI [1])
Systemic Radiation Therapy | Therapeutic radiology procedure Focal | Radiopharmaceuticals | Strontium | Samarium
Item
5. systemic radiation therapy within 4 weeks, prior focal radiotherapy within 2 weeks, or radiopharmaceuticals (strontium, samarium) within 8 weeks prior to the first dose of study treatment.
boolean
C2985381 (UMLS CUI [1])
C1522449 (UMLS CUI [2,1])
C0205234 (UMLS CUI [2,2])
C0182638 (UMLS CUI [3])
C0038467 (UMLS CUI [4])
C0036147 (UMLS CUI [5])
Immunosuppressive Agents | CORTICOSTEROIDS FOR SYSTEMIC USE
Item
6. use of immunosuppressive medications within 4 weeks or systemic corticosteroids within 2 weeks prior to first dose of study treatment.
boolean
C0021081 (UMLS CUI [1])
C3653708 (UMLS CUI [2])
Cancer Other | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated | Exception Carcinoma in Situ Treated | Exception Disease Free Duration
Item
7. other prior malignancy, except for adequately treated basal or squamous cell skin cancer or in situ cancers; or any other cancer from which the patient has been disease-free for at least 3 years.
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0553723 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0007099 (UMLS CUI [4,2])
C1522326 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0012634 (UMLS CUI [5,2])
C0332296 (UMLS CUI [5,3])
C0449238 (UMLS CUI [5,4])
CNS metastases Untreated
Item
8. active, untreated central nervous system metastases.
boolean
C0686377 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
Autoimmune Disease
Item
9. active autoimmune disease or a documented history of autoimmune disease.
boolean
C0004364 (UMLS CUI [1])
Diverticulitis
Item
10. active diverticulitis.
boolean
C0012813 (UMLS CUI [1])
Cardiovascular Disease | Congestive heart failure | Poor hypertension control
Item
11. significant cardiovascular disease including chf or poorly controlled hypertension.
boolean
C0007222 (UMLS CUI [1])
C0018802 (UMLS CUI [2])
C0421190 (UMLS CUI [3])
Impaired gastrointestinal system function | Gastrointestinal Disease Changing Absorption Sunitinib
Item
12. impairment of gastrointestinal function or gastrointestinal disease that may alter the absorption of sunitinib.
boolean
C0232459 (UMLS CUI [1])
C0017178 (UMLS CUI [2,1])
C0392747 (UMLS CUI [2,2])
C0237442 (UMLS CUI [2,3])
C1176020 (UMLS CUI [2,4])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial